Radius Health (NASDAQ:RDUS) Shares Down 7.9%

Radius Health Inc (NASDAQ:RDUS)’s stock price dropped 7.9% during mid-day trading on Monday . The company traded as low as $23.18 and last traded at $23.71, approximately 1,768,565 shares traded hands during trading. An increase of 217% from the average daily volume of 558,732 shares. The stock had previously closed at $25.75.

RDUS has been the subject of a number of research reports. BidaskClub downgraded Radius Health from a “buy” rating to a “hold” rating in a report on Thursday, October 3rd. Citigroup upgraded Radius Health from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $24.00 to $40.00 in a report on Thursday, August 29th. Morgan Stanley initiated coverage on Radius Health in a report on Thursday, September 5th. They set a “buy” rating and a $43.00 price objective for the company. Cowen reiterated a “hold” rating on shares of Radius Health in a report on Thursday, August 8th. Finally, ValuEngine downgraded Radius Health from a “sell” rating to a “strong sell” rating in a report on Wednesday, October 2nd. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the stock. Radius Health has an average rating of “Hold” and an average target price of $36.50.

The company has a quick ratio of 4.28, a current ratio of 4.38 and a debt-to-equity ratio of 6.75. The stock has a 50 day simple moving average of $26.59 and a two-hundred day simple moving average of $23.10. The stock has a market capitalization of $1.09 billion, a P/E ratio of -4.86 and a beta of 0.78.

Radius Health (NASDAQ:RDUS) last posted its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.77) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.86) by $0.09. The firm had revenue of $41.04 million during the quarter, compared to the consensus estimate of $40.60 million. Radius Health had a negative return on equity of 368.58% and a negative net margin of 127.22%. The business’s revenue was up 81.4% compared to the same quarter last year. During the same period last year, the company earned ($0.99) earnings per share. Sell-side analysts predict that Radius Health Inc will post -3.24 earnings per share for the current fiscal year.

A number of hedge funds have recently bought and sold shares of the business. Ladenburg Thalmann Financial Services Inc. increased its stake in shares of Radius Health by 3,130.7% in the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,423 shares of the biopharmaceutical company’s stock valued at $59,000 after purchasing an additional 2,348 shares during the last quarter. Pictet Asset Management Ltd. grew its position in Radius Health by 19.0% during the 2nd quarter. Pictet Asset Management Ltd. now owns 288,536 shares of the biopharmaceutical company’s stock worth $7,029,000 after acquiring an additional 46,036 shares during the last quarter. Nuveen Asset Management LLC bought a new stake in Radius Health during the 2nd quarter worth $13,766,000. Price T Rowe Associates Inc. MD grew its position in Radius Health by 51.4% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 3,875,313 shares of the biopharmaceutical company’s stock worth $94,403,000 after acquiring an additional 1,314,899 shares during the last quarter. Finally, Cubist Systematic Strategies LLC grew its position in Radius Health by 164.9% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 41,946 shares of the biopharmaceutical company’s stock worth $1,022,000 after acquiring an additional 26,110 shares during the last quarter.

Radius Health Company Profile (NASDAQ:RDUS)

Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator to treat breast cancer.

Recommended Story: What is range trading?

Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.